Effect of Sitagliptin on Graft Function Following Islet Transplantation
Recruitment status was: Recruiting
|First Received Date ICMJE||February 26, 2009|
|Last Updated Date||February 15, 2011|
|Start Date ICMJE||July 2009|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
||Islet function as measured by hyperglycemic clamp [ Time Frame: 3 and 12 months ± 2 weeks after islet infusion ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT00853944 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Change in insulin requirement (absolute and % decrease from pre-transplant dose) [ Time Frame: 1 week prior to stopping the study ]|
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Effect of Sitagliptin on Graft Function Following Islet Transplantation|
|Official Title ICMJE||A Randomized Controlled Trial to Determine if Sitagliptin Will Enhance Islet Graft Function When Given for 1 Year Following Transplantation|
|Brief Summary||Islet transplantation requires a large number of islets required to achieve insulin independence and the function of the transplanted islets progressively declines over time. Evidence from animal studies and human islets in culture suggests that increasing GLP-1 levels could help with both of these problems. This study is designed to test this hypothesis using sitagliptin in a randomized clinical trial.|
Hypothesis: Sitagliptin taken for 12 months after an islet infusion will significantly improve islet function compared with a control group.
Purpose: To determine if sitagliptin given at the time of an islet cell transplant (ICT) results in improved islet graft function at 3 and 12 months post-transplant.
Study design: prospective, randomized, double-blind, single-centre, placebo-controlled trial.
Sample size calculation for primary outcome.
The primary outcome (stimulated insulin secretion) is a continuous variable that is normally distributed. Our previous clamp studies show an expected standard deviation of around 20% and we wish to be able to detect an increase of 33%. The result will be calculated both with and without adjustment for the number of IE / kg that a patient has received, since the literature is not clear on this issue. Analysis will be done using a two-sided t test. Sample size is estimated using an approximation of Lehr's formula for 80% power and 2-sided significance level of 5%.
m = 16 where d = δ δ = 33%, σ = 20% d 2 σ The calculation indicates a need for 6 patients per arm or a total of 12 patients for the 2 arms.
Ability of our site to perform the study
Since starting in 2003, we have performed 75 islet infusions in 31 patients, averaging one infusion per month. We are 1 of the 4 most active sites in North America (Edmonton, Miami, Minnesota are the others). We have a list of patients activated and waiting for a suitable islet donor. We anticipate that the great majority of patients will choose to participate in this trial. We should easily be able to perform the required 12 islet infusions within 2 years. The advantage of performing this study in a single therapy is the ability to keep constant variables such as eligibility criteria for recipients and choice of immunosuppressive drugs that differ considerably between centres. This approach increases the chances that the question posed will be answered by the study.
Eligible patients Eligible patients will be those in our transplant program who are about to undergo an infusion of donor islets. Criteria for entry into our program are as described (Warnock et al Arch Surg 2005;140:735). All eligible patients will be offered a chance to enter the study. Patients will need to sign an informed consent that has been approved by the Clinical Research Ethics Board of the University of British Columbia.
Randomization and Blinding Random numbers will be computer generated and placed in opaque sealed, numbered envelopes. The ratio of sitagliptin and placebo will be 1:1. The pharmacist associated with the islet transplant team will be the only team member with knowledge of the code for sitagliptin and placebo. Randomization will be done in blocks of four. The advantage of block randomization is to allow similar distribution among groups of any changes in performance of islet transplantation, such as new immunosuppression regimens, that could arise during the course of the study. There will not be any stratification. Randomization will be done just prior to islet infusion so that patients receiving either placebo or sitagliptin will be given their medication before receiving islets.
The subject and the investigators obtaining consent, performing the transplant, providing post-transplant care and performing the hyperglycemic clamp will be blind as to whether a subject is receiving sitagliptin or placebo. The placebo will be supplied by Merck and will be identical in appearance to sitagliptin. Sitagliptin and the placebo will be stored in the VGH pharmacy.
When a subject consents to participate in the study, the investigator obtaining the consent will contact the pharmacy. The pharmacy will open the next randomization envelope and dispense the medication (sitagliptin or placebo). Ongoing supply of the medication will be provided by the pharmacy in the transplant clinic during routine follow-up visits for post-transplant care.
All aspects of the transplantation procedure, immunosuppressive therapy and ancillary care will be performed as described (Warnock et al Arch Surg 2005;140:735) and will be similar for all patients for the duration of the study. The indications for stopping or restarting insulin are those recommended by the metabolic monitoring committee of the Collaborative Islet Transplant Registry. This will eliminate subjective investigator judgments that could affect one of the secondary endpoints (insulin dose).
Assessment of endpoints
Primary: Maximum insulin secretory capacity will be determined by a hyperglycemic glucose clamp, performed as described (Al Ghofaili et al Transplantation 2007;83:24). This will be performed at 3 and 12 months ± 2 weeks after islet infusion, with the subject having received either sitagliptin or placebo during this period. The medication will be stopped for 48 hours before the clamp to allow washout. A positive result would suggest that sitagliptin had increased functional islet mass, not that it was acting as a short-term secretagogue. The values will be expressed both as absolute numbers and as divided by the number of IE / kg received as it is not clear from the literature which is the better measurement. A baseline fasting C peptide will be drawn prior to the islet infusion.
Secondary: Patients are followed closely post transplant to maintain tight glucose control. Insulin adjustment and glucose targets are as described. The average daily insulin requirement in the week before transplant and in the week prior to stopping the study will be used for calculation. A positive result would be consistent with either an increase in functional islet mass or stimulation or insulin secretion.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 3|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
|Condition ICMJE||Islet Transplantation|
|Intervention ICMJE||Drug: sitagliptin
Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE||12|
|Estimated Completion Date||July 2011|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||20 Years to 65 Years (Adult)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Canada|
|Removed Location Countries|
|NCT Number ICMJE||NCT00853944|
|Other Study ID Numbers ICMJE||H08-01947|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Dr. David M. Thompson, University of British Columbia|
|Study Sponsor ICMJE||University of British Columbia|
|Collaborators ICMJE||Merck Sharp & Dohme Corp.|
|Information Provided By||University of British Columbia|
|Verification Date||February 2011|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP